8-KEarnings & ResultsMaterial AgreementsFinancial Events+2

BRISTOL MYERS SQUIBB CO 8-K Report, Material Agreement (Dec 27, 2006)

Filed December 27, 2006For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on December 27, 2006, detailing significant events from December 21, 2006. The company entered into a new $2.0 billion Five Year Competitive Advance and Revolving Credit Facility Agreement, replacing a similar facility from December 2004. This move provides continued financial flexibility and access to capital. In addition to financial arrangements, BMY announced it has reached an agreement in principle with the U.S. Department of Justice and the U.S. Attorney’s Office for the District of Massachusetts to settle investigations concerning drug pricing and sales/marketing practices. This settlement, pending DOJ approval, is a crucial development that could resolve significant legal liabilities. The company also lowered its full-year 2006 GAAP earnings per share guidance while reaffirming its non-GAAP guidance, indicating potential accounting impacts on reported earnings.

Key Highlights

  • 1Entered into a new $2.0 billion Five Year Competitive Advance and Revolving Credit Facility, replacing a prior agreement.
  • 2The new credit facility provides continued access to funding for the company and its subsidiaries.
  • 3Reached an agreement in principle with the U.S. Department of Justice and U.S. Attorney's Office for the District of Massachusetts to settle investigations into drug pricing and sales/marketing activities.
  • 4The settlement is subject to final approval by the U.S. Department of Justice.
  • 5Lowered full-year 2006 GAAP earnings per share guidance.
  • 6Reaffirmed full-year 2006 non-GAAP earnings per share guidance.

Frequently Asked Questions

The new $2.0 billion Five Year Competitive Advance and Revolving Credit Facility Agreement provides Bristol-Myers Squibb Company and its subsidiaries with continued financial flexibility and access to capital. It replaces a similar facility that was terminated concurrently.

The agreement in principle with the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts aims to settle investigations related to the company's drug pricing, and sales and marketing activities. This development is significant as it could resolve potential legal liabilities and regulatory concerns, although it is pending final approval.

The press release announcing the guidance change indicates that Bristol-Myers Squibb is lowering its full-year 2006 earnings per share guidance on a GAAP (Generally Accepted Accounting Principles) basis. The reasons for this specific adjustment are not detailed in this 8-K filing but are likely related to factors impacting reported accounting figures. The company reaffirmed its non-GAAP guidance, suggesting that the adjustment might not reflect underlying operational performance.

The new credit facility contains customary terms and conditions, similar to the previous agreement. These include limitations on consolidations, mergers, sales of assets, and incurrence of liens, as well as requirements to maintain a specific ratio of consolidated net indebtedness to consolidated capitalization. Borrowings are permitted from the Company, its U.S. subsidiaries, and non-U.S. subsidiaries, with guarantees from the Company for subsidiary borrowings.